Market Newsdesk

December 17, 2020

Companies to develop compatibility of Philips’ MR Ingenia 3.0T and 1.5T systems with the InSightec Exablate Neuro platform

Amsterdam, the Netherlands and Haifa, Israel –

Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology and InSightec, a global healthcare company focused on the therapeutic power of acoustic energy, today announced a collaboration to expand access to MR-guided focused ultrasound for incisionless neurosurgery. By developing compatibility between Philips’ advanced MR systems and the Exablate Neuro platform from InSightec, the two companies will support expanded access to MR-guided focused ultrasound for the treatment of Essential Tremor and other neurological disorders. The expansion of access to this innovative treatment option has the potential to significantly improve the patient and staff experience, enhance health outcomes and lower the cost of care.

Essential Tremor is a neurological condition that typically causes shaking of the hands, head and voice, and may also cause shaking of the legs and trunk. The tremor begins mildly and progresses over time, and in some patients, is severe enough to interfere with daily activities, such as personal care, eating or getting dressed. Essential Tremor is one of the most common movement disorders in the world [1]. MR-guided focused ultrasound uses high-intensity sound waves, guided by magnetic resonance imaging, to target and treat the area of the brain responsible for the tremor. The incisionless treatment option is often performed in an outpatient setting, with many patients showing immediate tremor relief with minimal complications.

“As a leading innovator in MR imaging to support precise diagnosis and targeted therapies, we continue to expand the role of MR in providing precision guidance for minimally invasive therapy solutions into new treatment areas,” said Arjen Radder, General Manager for MR at Philips. “By partnering with InSightec we are expanding access to Philips’ advanced MR capabilities to a wider range of healthcare providers, including neurosurgery practices both in-hospital and in outpatient settings, as well as the global research community. Together, we aim to advance towards clear care pathways with predictable outcomes for every patient.”

“InSightec is committed to expanding patient access for MR-guided focused ultrasound, which is rapidly being adopted as a standard of care worldwide for treating Essential Tremor, as well as continuing to develop a research pipeline for the treatment of many other disorders,” said Maurice R. Ferré MD, InSightec CEO and Chairman of the Board of Directors. “Partnering with Philips will help increase adoption of our innovative technology to transform patient care.”

The partnership will involve the development of compatibility between the InSightec Exablate Neuro platform and Philips’ MR Ingenia Elition 3.0T, Ingenia 3.0T and Ingenia 1.5T systems. This includes the Ambition 1.5T MR, the industry’s first and only commercially available fully sealed magnet for more productive, helium-free operations [2]. Philips’ MR therapy portfolio also includes its Ingenia MR-OR intraoperative MR for use during neurosurgical procedures, as well as its leading MR-only radiotherapy applications, which enable clinicians to quickly execute complete imaging protocols for prostate, female pelvis, brain, head and neck, and spine.

The parties expect market introduction for the compatible systems in 2023 with offerings available for both existing and new customers.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938289/
[2] Compared to the Ingenia 1.5T ZBO magnet.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: [email protected]

Lyndsay Isaksen
G&S Business Communications for InSightec
Tel.: +1 917 595 3032 
E-mail: [email protected]

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About InSightec

InSightec is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy. The company’s Exablate® Neuro platform focuses sound waves, guided by MRI, to provide tremor relief to patients with Essential Tremor and Tremor-dominant Parkinson’s Disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. InSightec is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Shanghai and Tokyo. For more information, please visit: www.insightec.com.

Attachments

• The Philips MR Ingenia Ambition 1.5T
• MR-guided focused ultrasound for incisionless neurosurgery
• InSightec logo

WILMINGTON, DEL., Dec. 17, 2020 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ: IDCC), a mobile and video technology research and development company, today announced the finalization of Versatile Video Coding (VVC) and Video-based Point Cloud Compression (V-PCC) video standards at MPEG. The standards bring new capabilities and will enable more interactive experiences within the video ecosystem. The new VVC standard improves high-efficiency video coding (HEVC) performance by 50%, while V-PCC represents the first MPEG compression standard for dynamic point cloud content for immersive video experiences.

The hallmark of VVC is its improved performance over HEVC, which enables the same quality of video at half the bitrate. This characteristic is integral to support the distribution and streaming of increasingly immersive video, especially as video grows to represent more than 80% of internet traffic bandwidth. An improvement upon its predecessors, VVC also supports enhanced features like layered coding, sub-pictures, and adaptive resolution coding which creates an environment for new applications like cloud gaming, immersive and 360°video content distribution, and 8K and High Dynamic Range televisions.

The new V-PCC standard leverages existing video codecs, like HEVC and VVC, to compress high-bandwidth content and enable new services and experiences. Point Clouds are sets of tiny “points” grouped to make a 3D image and have become a popular method for AR and VR video composition, 3D modeling, and geographic mapping. Each Point Cloud video frame typically has hundreds of thousands to millions of points, which translates to a massive amount of bandwidth – typically several Gbps uncompressed. V-PCC can achieve a compression ratio of 300 to 1 for lossy content and thus enables increasingly immersive experiences like AR telepresence, free viewpoint television, and extended reality (XR). Using HEVC as the underlying codec, the compression standard can also be applied to commercially available smartphones.

“The standardization of VVC and V-PCC codecs unlocks new frontiers in our video and entertainment industry” said Lionel Oisel, Research & Innovation Lab Director at InterDigital. “MPEG work is inherently competitive and collaborative, and we take pride in InterDigital’s leadership and contributions to make these new codecs a reality. Standardization of the VVC and V-PCC codecs encourages their widespread adoption to support the crisp, low-latency deployment of immersive video experiences through existing network infrastructure and devices.”

InterDigital has played a pivotal role in the VVC standardization project since its inception and held key roles in the project’s 360° video and HDR activities. InterDigital was a top contributor among the roughly 70 companies that contributed to the development of the standard and co-led several of the VVC ad-hoc groups.

In the development of V-PCC, InterDigital’s R&I team participated in the initiation of the PCC project at MPEG and was one of the initial, and top, contributors. InterDigital chaired the PCC Ad hoc Group, responsible for coordinating all PCC activity, the development of reference software, and call for proposals for Point Cloud Compression activity. InterDigital also participated in the specification edits throughout the MPEG meetings.

The Final Draft International Standard (FDIS) versions of the VVC and V-PCC standards were both issued at the MPEG 131^st meeting for the ITU Telecommunication Standardization Sector (ITU-T) and ISO/IEC Information Technology ballots. VVC received ITU-T approval in August, and on the ISO/IEC side, the final FDIS approval ballot for VVC will close in January 2021.

About InterDigital
^®

InterDigital develops mobile and video technologies that are at the core of devices, networks, and services worldwide. We solve many of the industry’s most critical and complex technical challenges, inventing solutions for more efficient broadband networks, better video delivery, and richer multimedia experiences years ahead of market deployment. InterDigital has licenses and strategic relationships with many of the world’s leading technology companies. Founded in 1972, InterDigital is listed on NASDAQ and is included in the S&P MidCap 400^® index.

InterDigital is a registered trademark of InterDigital, Inc.

For more information, visit: www.interdigital.com.

InterDigital Contact:
Roya Stephens
Email: [email protected]
+1 (202) 349-1714

Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.

Berlin, Germany, December 17, 2020 – Glycotope GmbH, an oncology/immuno-oncology platform company built on world-leading glycobiology expertise, today announces that is has signed an agreement to license a humanized, tumor-specific antibody (GlycoBody) targeting an aberrantly glycosylated tumor associated form of MUC1 (TA-MUC1) to ONK Therapeutics Ltd. (ONK), an innovative natural killer (NK) cell therapy company.

The GlycoBody will be integrated into ONKs pre-clinical program ONKT103, for solid tumors. ONK’s unique platform approach combines the expression of a chimeric antigen receptor (CAR) and a high affinity, membrane-bound TNF related apoptosis inducing ligand variant (TRAILv).

Multiple solid tumor types express the mucin MUC1, including non-small cell lung cancer, breast cancer and ovarian cancer. MUC1 is also expressed on healthy tissues and previous attempts to target this antigen have proved problematic. By utilizing Glycotope’s antibody, ONK can tailor its CAR to target the glycosylation pattern distinct to tumor associated MUC1 (TA-MUC1) with specific recognition of the carbohydrate antigens Tn and T on MUC1. The expression of these antigens is restricted to cancer cells and by targeting them ONK hopes to increase tumor-specificity and reduce the potential for on-target off-tumor toxicity.

Henner Kollenberg, Managing Director of Glycotope GmbH commented
“This is an exciting development. Our technology platform has identified the glycosylation pattern that could enable ONK to unlock the potential of TA-MUC1 as a solid tumor target with their unique dual-targeted NK cell therapy approach. This represents further validation of our platform’s ability to
enable the development of highly-specific immunotherapies across a broad range of cancer indications.”

Contact Information:

About Glycotope

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop highly tumor-specific monoclonal antibodies called GlycoBodies. GlycoBodies bind to targets (GlycoTargets) tumor-specific carbohydrate structure dependent, enabling the development of highly-specific immunotherapies across a broad range of cancer indications. Glycotope has to date discovered in excess of 150 GlycoTargets with GlycoBodies against eight of these targets currently under development.

Each GlycoBody can be developed in an array of modalities with different modes of action such as Antibody-drug conjugates, CAR/cell therapies or bispecifics, providing a unique offering in the (immuno) oncology space. Currently six clinical and pre-clinical programs based on the GlycoBody technology are under development by Glycotope or its licensing partners. Visit www.glycotope.com.

About ONK Therapeutics – www.onktherapeutics.com
ONK Therapeutics Ltd is an innovative cell therapy company dedicated to developing the next generation of ‘off-the-shelf’, dual-targeted NK cell therapies targeting solid and hematological cancers.

Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumor antigen and a TNF-related apoptosis-inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This unique approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor-specific antigen) and extrinsic (e.g. signaling through the death receptor pathway) apoptotic pathways and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen-independent TRAILv. 

ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned US subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego. Shareholders include Acorn Bioventures, ALSHC (principally Seamus Mulligan), and Enterprise Ireland.

SANTA CLARITA, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) — BioSolar, Inc. (OTC:BSRC) (“BioSolar” or the “Company”), a developer of energy storage technology and materials, today announced that its wholly owned subsidiary, NewHydrogen, Inc., has entered into a sponsored research agreement with the University of California Los Angeles (“UCLA”) to develop a technology to reduce the cost of green hydrogen production.

This 12-month research program with UCLA will commence January 1, 2021, under the direction of Dr. Yu Huang, Vice Chair for Graduate Studies, Department of Materials Science and Engineering. The program will focus on the discovery of efficient and stable earth-abundant material-based catalysts for hydrogen production through electrolysis. Dr. Huang, the recipient of numerous awards and global recognition, is leading a team that is creating methodologies to apply the latest developments in nanoscale materials and nanotechnology to impact a wide range of technologies including materials synthesis, catalysis, fuel cells, biomedical and devices applications.

Electrolysis, the process of using electricity to split water into hydrogen and oxygen molecules, is a promising option for “green hydrogen” produced by renewable solar generated electricity. Currently, the two leading technologies in the water electrolyzer market are alkaline and acidic proton exchange membrane-based (PEM), both of which have similar market share. PEM electrolyzers, are the more modern variants and show higher efficiency, lower energy consumption, and produces hydrogen of higher purity than alkaline water electrolyzers. Most importantly, PEM electrolyzers offer high dynamic ranges which are well suited for the intermittent nature of renewable energy such as solar and wind. However, one of the main challenges for widespread adoption of PEM electrolyzers is their reliance on expensive precious metals like platinum and iridium – literally stardust found only in asteroids.

“We are thrilled to work with Dr. Huang and her team at UCLA and share the mutual goal of developing catalysts made with earth abundant materials that could efficiently electrolyze water into hydrogen and oxygen at a lower cost,” said Dr. David Lee, CEO of BioSolar. “While we embark on this new program in the high growth category of hydrogen production, we remain committed to our existing battery technology development program with the focus of commercializing a silicon anode capable of improving the efficiency and lowering the cost of electric vehicle design and production.”

About BioSolar, Inc.

BioSolar is developing breakthrough technologies to increase the storage capacity, lower the cost and extend the life of lithium-ion batteries for electric vehicles. The need for such breakthroughs is critical to meet the expected demand of the rapidly growing global electric vehicle battery market, which is forecast to exceed $90 billion by 2025. A lithium-ion battery contains two major parts, a lithium-filled cathode and a lithium-receiving anode, that function together as the positive and negative sides of the battery. BioSolar is developing innovative technologies that will enable the use of inexpensive silicon as the anode material to create next generation high energy and high-power lithium-ion batteries for electric vehicles. Founded with the vision of developing breakthrough energy technologies, BioSolar’s previous successes include the world’s first bio-based backsheet for use in solar panels.

To learn more about BioSolar, please visit our website at https://www.biosolar.com.

About NewHydrogen, Inc.

NewHydrogen, Inc., a wholly owned subsidiary of BioSolar, Inc., is focused on developing a breakthrough electrolyzer technology to lower the cost of green hydrogen. Hydrogen is the cleanest and most abundant fuel in the universe. It is zero-emission and only produces water vapor when used. However, hydrogen does not exist in its pure form on Earth so it must be extracted. For centuries, scientists have known how to split water into hydrogen and oxygen using a simple and elegant device called an electrolyzer. Unfortunately, electrolyzers are expensive and rely on rare earth materials such as platinum and iridium – literally stardust found only in asteroids. These materials account for nearly 50% of the cost of electrolyzers. NewHydrogen is developing a breakthrough electrolyzer technology to replace rare earth materials with inexpensive earth abundant materials to help usher in a green hydrogen economy that Goldman Sacks estimated to be worth $12 trillion by 2050.

To learn more about NewHydrogen, please visit our website at https://www.NewHydrogen.com.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company with the United Stated Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONTACT INFORMATION

Investor Relations Contact: 
Tom Becker 
BioSolar, Inc.
[email protected]
(877) 904-3733

Company announcement – No. 63 / 2020

Copenhagen, December 17, 2020 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) has received information on transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached files.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Zealand Pharma’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand Pharma markets V-Go^®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand Pharma-invented peptide therapeutics.

Zealand Pharma was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.  

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Mads Kronborg
Head of Investor Relations & Communication
Phone: +45 5060 3707
Email: [email protected]

For U.S. Media

David Rosen
Argot Partners
Phone: 212-600-1902
Email: [email protected]

Attachments

• 20_201214_Notification_GKR_s
• 21_201214_Notification_GKR_s
• 22_201214_Notification_GKR_s
• 63-2020 Transactions in Zealand Pharma shares and or related securities

VANCOUVER, British Columbia, Dec. 17, 2020 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”). Clean Power is encouraged by and applauds Canada’s Federal Government and Canada’s Minister of Natural Resources, for the launch of the Hydrogen Strategy for Canada on December 16, 2020¹. Canada’s Hydrogen Strategy paves the way towards realizing Canada’s goal of carbon neutrality by 2050 as part of the global fight against climate change. Canada now joins a growing list of countries in recognizing the critical role of hydrogen in the transition of energy use to decarbonize segments of the economy, such as the fueling of vehicles, that have a disproportionately large impact on the emission of CO₂.

As previously announced on October 28, 2020, the Company invested in PowerTap Hydrogen Fueling, a company that is building out cost-effective hydrogen fueling infrastructure through its environmentally friendly intellectual property, product design for the modularized and lowest tier production cost of hydrogen. With Canada seeking to position itself as a global hydrogen leader by establishing a plan to net-zero carbon emissions by 2050, the Company views this as a tremendous business opportunity for Canada’s leading hydrogen and fuel cell technology and energy companies. In this regard and aligned with the Company’s investment policy to invest for purposes of generating returns from capital appreciation and investment income, the Company will continue to actively seek investment opportunities in Canada’s hydrogen fueling sector. A copy of the Company’s investment policy may be viewed at: https://cleanpower.capital/investment-policy/

The CEO of Clean Power, Mr. Joel Dumaresq stated, “We are thrilled by the ambitious plans laid out in the Hydrogen Strategy for Canada. This strategy sets to make Canada a global leader in hydrogen by 2050, with up to 30% of Canada’s energy to be hydrogen-based and a plan to build a national hydrogen fueling station network. While Clean Power’s current investment in the clean energy sector is based in the U.S., this new Canadian framework provides us with an exciting opportunity to identify new potential renewable energy investments in Canada.”

ABOUT CLEAN POWER CAPITAL CORP.

Clean Power is an investment company, that specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in our investments. A copy of Clean Power’s amended and restated investment policy may be found under the Company’s profile at www.sedar.com.

ON BEHALF OF THE CLEAN POWER CAPITAL CORP. BOARD OF DIRECTORS

“Joel Dumaresq”

Joel Dumaresq CEO
+1 (604) 687-2038
i[email protected]pital

Learn more about Clean Power by visiting our website at: https://cleanpower.capital/

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Notice Regarding Forward Looking Information:

This press release contains “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Clean Power. Some assumptions include, without limitation, the development of hydrogen powered vehicles by vehicle makers, the adoption of hydrogen powered vehicles by the market, legislation and regulations favoring the use of hydrogen as an alternative energy source, the Company’s ability to build out its planned hydrogen fueling station network, and the Company’s ability to raise sufficient funds to fund its business plan. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur or be achieved. This press release contains forward-looking statements pertaining to, among other things, the timing and ability of the Company to complete any potential investments or acquisitions, if at all, and the timing thereof. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and, in some instances, to differ materially from those anticipated by the Company and described in the forward-looking information contained in this press release.

Although the Company believes that the material factors, expectations and assumptions expressed in such forward- looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward- looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

¹ https://www.nrcan.gc.ca/changements-climatiques/hydrogen-strategy/23080